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ABSTRACT 
~ 
Purpose: To determine the validity of main pulmonary artery diameter (MPAD) 
as a marker of pulmonary hypertension in scleroderma patients with and without 
interstitial lung disease (llO). 
Materials and Methods: We cross-referenced the radiologic database with 
medical records to identify patients with both computed tomography (CT) scans 
of the chest and right-heart catheterization separated by no more than six 
months. Computed tomography scans were reviewed to determine MPAD and 
extent of IlO for each patient. Ground glass opacity and fibrosis were individually 
scored by a single thoracic radiologist on a five-point scale. The same radiologist 
also determined the quality of delineation for the great vessels. MPAD was 
calculated based on the average of measurements taken from two separate 
observers. Mean pulmonary arterial pressures (mPAP) were determined by 
RHC. Patients were divided into either group A (n = 20) or group B (n = 27) 
based on the absence or presence of interstitial fibrosis respectively. Patients 
with available data from pulmonary function tests (PFTs) were divided into those 
with FVC > 70% predicted (Group C) and those with FVC < 70% predicted 
(Group D). Groups were compared using either the Student t test or Mann-
Whitney U test depending on the distribution of each variable under 
consideration. Either the Pearson correlation coefficient or the Spearman rank-
correlation coefficient was calculated for each group to evaluate the relationship 
between MPAD and mPAP. 
Results: Groups A and B were similar with regard to MPAD (p = 0.28) and 
mPAP (p = 0.34) upon Mann-Whitney U testing. MPAD was strongly correlated 
with mPAP in both Group A (r = 0.68, P = 0.001) and Group B (r = 0.70, P < 
0.0001). The correlation between MPAD and mPAP in Group C (r = 0.69, P = 
0.002) was substantially higher than that in Group 0 (r = 0.42, P = 0.11). 
Conclusion: In our patient sample with scleroderma, MPAD is strongly 
correlated with mPAP and may indicate the development of pulmonary 
hypertension regardless of the presence of mild to moderate interstitial fibrosis. 
An increase in the severity of restrictive lung disease as measured by FVC 
appears to attenuate the correlation between MPAO and mPAP. 
CHAPTER 1 
INTRODUCTION 
Scleroderma refers to a fibrotic thickening of the skin that frequently 
becomes clinically apparent in several different pathologic states involving 
connective tissue derangements of production and organization. Though strictly 
only a symptom, the use of this term has, over time, become synonymous with 
the disease known as systemic sclerosis (SSc). Regardless of how one chooses 
to use the label "scleroderma", the fibrotic mechanism underlying this finding may 
lead to other systemic manifestations that overlap across the various connective 
tissue diseases. As a model illness for which scleroderma is the most clinically 
evident symptom, SSe can involve many organs throughout the body and show 
marked heterogeneity in the time course of disease progression. 
Concerning SSe, progressive pulmonary dysfunction has become the 
primary concern, following the release of ACE inhibitors for scleroderma renal 
crisis, of those investigating mortality linked to this disease. Indeed, pulmonary 
complications have steadily replaced scleroderma renal crisis as the primary 
cause of SSc-related death with approximately 500/0 of mortalities resulting from 
an associated decline in lung function [1]. Current research is focused on 
identifying underlying visceral involvement in the early stages so that treatment 
may be initiated in a timely fashion. Pulmonary involvement in SSc ranges from 
minor parenchymal fibrosis to severe pulmonary hypertension (PH). To 
complicate matters, PH in SSc can result from the progression of interstitial lung 
disease (ILD) or develop as an isolated pulmonary arterial hypertension (PAH), 
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itself a major mortality factor independent of ILD extent [2]. The clinical 
evaluation of pulmonary hypertension has proven challenging in the SSc 
population with 20% of connective tissue disease patients having undiagnosed 
severe PAH [3] and 14% of SSc patients developing severe PH in the face of 
initial echocardiographic evidence to the contrary [4]. With regard to screening, 
both the invasive nature of right heart catheterization (RHC) and the lack of 
echocardiographic sensitivity have led to an exploration of alternative methods 
for establishing the diagnosis of PH in general populations at risk of such 
involvement [5-10]. Computed tomography (CT or CAT) has been investigated 
as a potential screening device capable of simultaneously assessing the degree 
of parenchymal lung disease and the level of pulmonary arterial pressure 
(PAP)[6]. Many studies support the use of chest CT in predicting PH [5-9] with 
some reporting correlation coefficients as high as 0.83 between main pulmonary 
artery diameter (MPAD) measurements and PAP [8]. With continued research in 
this field, it has become increasingly evident that this correlation may be 
substantially altered by the presence of specific comorbidities. For example, 
pulmonary fibrosis has recently been found to substantially alter the correlation 
between MPAD and PAP [11, 12]. 
In light of the recent identification of pulmonary fibrosis as a complicating 
factor and when considering the heterogeneity of clinical presentation in SSc, it is 
necessary that the relationship between MPAD and PAP be closely examined in 
the scleroderma population. Furthermore, all but one previous study [13] have 
evaluated the utility of the MPAD measurement in mixed populations comprised 
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of very few SSc patients. This study will be the first to analyze the correlation 
between MPAD and PAP using a variety of chest CT protocols to access 
pulmonary involvement in a sample of scleroderma patients. In acknowledgment 
of the fact that a large number of cases of PAH occur in SSc patients with little to 
no fibrotic lung involvement and realizing that pulmonary fibrosis, when present, 
benefits most from early intervention, this study will focus on examining the 
correlation between MPAD and PAP in patients without the presence of fibrosis 
on chest CT as well as those with mild to moderate lung disease. 
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CHAPTER 2 
REVIEW OF LITERATURE 
2.1 SYSTEMIC SCLEROSIS OVERVIEW 
Systemic Sclerosis (SSc) is an autoimmune disease characterized by 
widespread mesenchymal cell activation that results in substantial extracellular 
matrix deposition and fibrosis throughout the body [14]. This disease is 
notoriously complex with an etiology that remains unclear. Dermal thickening, 
a.k.a. scleroderma, is seen in the vast majority of SSc cases. Visceral effects 
are also common and such involvement can progress on a subclinical level for 
many years [15]. Historically, visceral involvement in SSc has centered around 
the heart, lungs, kidneys, and gastrointestinal tract. Renal complications account 
for the majority of SSc-related deaths in the literature predating the release of 
ACE inhibitors [16-18]. This paradigm has since shifted with pulmonary 
complications now accounting for approximately 500/0 of deaths resulting from 
SSc [1]. With a wide range of potential organ involvement, patient prognosis in 
SSc is difficult to predict. Therefore, a significant body of literature has been 
devoted to arranging patients into symptomatically uniform groups for the 
purpose of establishing accurate prognostic models. 
In order to standardize the classification of SSc patients for research 
purposes, the American College of Rheumatology (ACR) adopted several criteria 
in 1980 that address the most common manifestations of this disease [19]. 
Using this system, the classification of suspected SSc cases depends on the 
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identification of either one major criterion or two minor criteria from a list of 
multiple disease characteristics. This classification allows patients being 
evaluated for SSc to be listed as either "definite" or "probable" regarding their 
disease status and comparisons between patient populations in the literature can 
be made using this system. A subclassification scheme has been proposed [14] 
based on the extent of cutaneous involvement and is commonly used in the 
clinic. The two main subtypes of SSc are limited cutaneous scleroderma (lcSSc) 
and diffuse cutaneous scleroderma (dcSSc). This model has been shown to 
define groups with significantly different prognoses. The study that led to this 
classification scheme incorporated data from SSc patients in whom twelve year 
survival for diffuse and limited scleroderma was 15% and 500/0 respectively [20]. 
More recently, Ferri et al. [15] have demonstrated a similar trend, though 
somewhat less in magnitude. In their study of Italian patients, the authors report 
a ten year survival of 750/0 in IcSSc, a significant difference from the 530/0 survival 
seen in the diffuse subtype [15]. Other factors such as seriologic profile and 
organ involvement, especially the lung, may also be associated with SSc 
cutaneous subtype [15, 17,20-22]. 
As mentioned earlier, pulmonary involvement has become the primary 
cause of death in SSc and much effort has been devoted to uncovering the 
nature of this involvement across different scleroderma subtypes. The remainder 
of this review will be largely devoted to a discussion of the pulmonary 
complications seen in SSc. The use of computed tomography (CT) in this 
population as a non-invasive tool, potentially capable of assessing the degree of 
7 
interstitial lung disease (ILD) in a given patient as well as identifying those 
subjects who may benefit from further evaluation for pulmonary hypertension 
(PH), will also be reviewed. 
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2.2 PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS 
2.2.1 Interstitial Lung Disease 
Bounded on either side by basement membrane, the interstitial 
compartment of the lung may become pathologically altered as the result of over 
150 different stimuli [23]. Interstitial lung disease is the name given to the wide 
range of such alterations originating within this compartment. Lung biopsy, 
bronchoalveolar lavage (BAL), pulmonary function testing (PFT), and CT are all 
methods currently utilized by clinicians to confirm the presence of ILD, with 
biopsy and subsequent pathologic evaluation being the gold standard for this 
diagnosis. Various histological patterns exist depending on the degree and 
distribution of inflammatory cell infiltration and fibrosis throughout the interstitium. 
Though originally considered to exclusively resemble a histopathological 
type of ILD known as usual interstitial pneumonia (UIP) [24], it has since been 
shown that pulmonary interstitial involvement in SSc frequently incorporates 
features of non-specific interstitial pneumonia (NSIP) [25]. In idiopathic 
pulmonary fibrosis (IPF), a disease classically characterized by the former 
histopathological pattern, patients with UIP demonstrate diminished survival 
when compared to those with NSIP [26]. In addition, a better prognosis has been 
linked with SSc-associated ILD in past studies [27,28] when compared to 
patients with IPF. Therefore" it may be expected that SS~,D..ali~l)j~ wjJ)) lJJP )OIjJJ 
have a worse prognosis than those with a predominately NSIP pattern of ILD. 
Bouros et al. [29] have demonstrated, however, that 1 O-year survival in SSc 
patients with NSIP did not differ significantly from those with UIP upon 
retrospective study. In fact, they found that survival depended on initial 
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physiologic measures taken from PFTs rather than histopathology [29]. As this 
finding contradicts that seen in IPF [26], the prognostic significance of histological 
typing in SSc-related ILD remains uncertain. 
In contrast to biopsy and pathologic examination, pulmonary function 
testing is a non-invasive and easily performed clinical assessment regularly used 
to detect the presence of ILD in SSc patients as well as monitor disease 
progression. Forced vital capacity (FVC) is one measure derived from PFTs that 
is widely used to evaluate the restrictive lung defect generated by SSc-related 
ILD. In a study by Steen et al. [30], lower values of FVC were associated with a 
decreased cumulative 1 O-year survival rate. Risk factors for severe restrictive 
lung disease in SSc include African American race and the diffuse cutaneous 
subtype [30]. Such factors may be related to a greater extent of inflammatory 
and fibrotic lung involvement in as much as FVC correlates with the severity of 
interstitial disease. Yet, as discussed below, FVC is only weakly associated with 
the extent of disease on CT and may not provide an accurate estimate of total 
interstitial lung involvement in SSc. 
2.2.2 Pulmonary Hypertension 
Pulmonary hypertension (PH) is a disorder characterized by elevated 
pulmonary arterial pressure (PAP) often leading to dyspnea and eventual right 
heart failure. In SSc, PH can result from the compression of capillaries due to 
progressive ILD, develop as an isolated pulmonary arterial hypertension (PAH) in 
which proliferation of the vascular wall leads to occlusion, or emerge as a 
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combination of these two processes. In a Canadian multicenter study [31] 
where 290/0 of patients were found to have elevated PAP, 54.8% had isolated 
PAH while 29.8% had PH secondary to ILD. In contrast, Launay et al. [32] found 
a prevalence of 18.3% for moderate to severe PH in SSc, regardless of the 
presence or absence of significant restrictive lung disease defined as an FVC < 
70% predicted. Risk factors for the development of PH in SSc include Raynaud's 
phenomenon that precedes skin manifestations by at least 3 years, FVC < 80% 
predicted, and fibrosis on high resolution chest CT [33]. The limited cutaneous 
subtype of SSc is associated with rapid progression of PH [21]. 
The screening of SSc patients for PH is an essential practice. Indeed, 
there is a propensity for elevated PAP to go unnoticed for many years in this 
population. For instance, Wigley et al. [3] uncovered a large group of patients, 
13.3% of those studied, from 50 separate community rheumatology clinics with 
PAH that had gone previously undetected. Perhaps more importantly, it has 
been shown in dcSSc-related ILD that PAH is an independent predictor of 
mortality [2]. While PFTs are often ordered when screening for PH, 
echocardiography and CT may be more suitable for this purpose. Carbon 
monoxide diffusing capacity (OLeo) has been explored as a possible functional 
correlate of PH [34-36] with conflicting results. A study by Mukerjee et al. [34] 
found a very weak correlation between OLeo and PAP. The tricuspid gradient 
(TG) on echocardiography exhibited a much stronger correlation with PAP [34] 
and has recently been incorporated into a composite index along with the CT-
derived measurement of main pulmonary artery diameter (MPAO) to screen for 
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PH [13]. Much of the remainder of this review will be devoted to a discussion 
concerning the utility of CT in evaluating PH. 
2.2.3 Computed Tomography 
In the SSc population, CT is widely employed as part of a complete 
workup of scleroderma lung disease. Aside from biopsy, computed tomography 
is the only means by which clinicians can directly visualize the inflammation and 
fibrosis within the lung. It is now standard practice for SSc patients to be 
evaluated using CT if dyspnea or abnormal PFTs are present. High resolution 
computed tomography (HRCT) has replaced conventional CT protocols as the 
gold standard for diagnosis of SSc-related IlO. The main difference between 
HRCT and conventional CT is the thickness of the slice of tissue being imaged 
by the scanner [37]. Increased distance between slices is also typical of HRCT 
protocols, making this imaging technique most suitable for diffuse lung disease 
such as that seen in SSc [37]. Multiple protocols [11, 38, 39] exist to quantify the 
extent of IlO on chest CT images. In general, most protocols grade interstitial 
involvement based on the amount of ground glass opacity (GGO), reticulation, 
and/or honeycombing appearing throughout the lung. Pulmonary function has 
been shown to correlate weakly with the extent of abnormality on chest CT [39-
41]. This finding suggests that PFTs alone are insufficient for monitoring the 
natural course of ILO in SSc. Thus, HRCT is essential not only for the evaluation 
of early disease, but also for tracking disease progression and response to 
treatment. 
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Aside from the utility of CT in detecting underlying ILD, this form of 
imaging has also been the topic of much research [5, 7, 8, 10-12,42] regarding 
the evaluation of PH. The pulmonary artery is easily visualized as it passes over 
the base of the heart on axial CT images and the measurement of MPAD has 
been found to correlate nicely with PAP [5, 7, 8]. Many of the studies which have 
examined this relationship have done so in groups of patients with an array of 
cardiopulmonary diagnoses. Only two studies [13, 36] have looked at the 
correlation between MPAD and measures of PH in SSc. While Pandey et al. [36] 
found MPAD to correlate with peak PAP on echocardiography, they concluded 
that CT-derived fibrosis score was a stronger determinant of PAP. Condliffe et 
al. [13] evaluated the relationship between MPAD and PAP measured by right 
heart catheterization in SSc and reported a correlation coefficient of 0.35. This 
correlation was stronger (r = 0.57) when excluding those patients with significant 
ILD defined as FVC < 700/0 predicted or extent of lung involvement > 20% on 
chest CT [13]. Similarly, prior studies in IPF [11] and generalized populations 
with pulmonary disease [12, 42] have suggested that pulmonary fibrosis 
attenuates the correlation between MPAD and PAP. The methods used by 
Condliffe et al. [13] to exclude patients with significant ILD, however, leave 
several questions unanswered regarding this observation. For instance, do PFT 
results and disease extent on HRCT equally affect the correlation between 
MPAD and PAP? Also, do patients with mild to moderate ILD show the same 
attenuation in the correlation coefficient? Continued research in this area may 
13 
reveal the answer to these questions and help further identify the role of CT in 
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3.1 ABSTRACT 
Purpose: To determine the validity of main pulmonary artery diameter (MPAD) 
as a marker of pulmonary hypertension in scleroderma patients with and without 
interstitial lung disease (llO). 
Materials and Methods: We cross-referenced the radiologic database with 
medical records to identify patients with both computed tomography (CT) scans 
of the chest and right-heart catheterization separated by no more than six 
months. Computed tomography scans were reviewed to determine MPAD and 
extent of IlD for each patient. Ground glass opacity and fibrosis were individually 
scored by a single thoracic radiologist on a five-point scale. The same radiologist 
also determined the quality of delineation for the great vessels. MPAO was 
calculated based on the average of measurements taken from two separate 
observers. Mean pulmonary arterial pressures (mPAP) were determined by 
RHC. Patients were divided into either group A (n = 20) or group B (n = 27) 
based on the absence or presence of interstitial fibrosis respectively. Patients 
with available data from pulmonary function tests (PFTs) were divided into those 
with FVC > 700/0 predicted (Group C) and those with FVC < 70% predicted 
(Group D). Groups were compared using either the Student t test or Mann-
Whitney U test depending on the distribution of each variable under 
consideration. Either the Pearson correlation coefficient or the Spearman rank-
correlation coefficient was calculated for each group to evaluate the relationship 
between MPAD and mPAP. 
Results: Groups A and B were similar with regard to MPAO (p = 0.28) and 
mPAP (p = 0.34) upon Mann-Whitney U testing. MPAD was strongly correlated 
with mPAP in both Group A (r = 0.68, P = 0.001) and Group B (r = 0.70, P < 
0.0001). The correlation between MPAD and mPAP in Group C (r = 0.69, P = 
0.002) was substantially higher than that in Group D (r = 0.42, P = 0.11). 
Conclusion: In our patient sample with scleroderma, MPAD is strongly 
correlated with mPAP and may indicate the development of pulmonary 
hypertension regardless of the presence of mild to moderate interstitial fibrosis. 
An increase in the severity of restrictive lung disease as measured by FVC 
appears to attenuate the correlation between MPAD and mPAP. 
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3.2 INTRODUCTION 
Progressive pulmonary dysfunction has become the primary concern, 
following the release of ACE inhibitors for scleroderma renal crisis, of those 
investigating mortality linked to Systemic Sclerosis (SSc). Indeed, pulmonary 
complications have steadily replaced scleroderma renal crisis as the primary 
cause of SSc-related death with approximately 50% of mortalities resulting from 
an associated decline in lung function [1]. Pulmonary involvement in SSc ranges 
from minor parenchymal fibrosis to severe pulmonary hypertension (PH). To 
complicate matters, PH in SSc can result from the progression of interstitial lung 
disease (ILD) or develop as an isolated pulmonary arterial hypertension (PAH), 
itself a major mortality factor independent of ILD extent [2]. The clinical 
evaluation of pulmonary hypertension has proven challenging in the SSc 
population with 20% of connective tissue disease patients having undiagnosed 
severe PAH [3] and 140/0 of SSc patients developing severe PH in the face of 
initial echocardiographic evidence to the contrary [4]. 
With regard to screening, both the invasive nature of right heart 
catheterization (RHC) and the lack of echocardiographic sensitivity have led to 
an exploration of alternative methods for establishing the diagnosis of PH in 
general populations at risk of such involvement [5-10]. Computed tomography 
(CT or CAT) has been investigated as a potential screening device capable of 
simultaneously assessing the degree of parenchymal lung disease and the level 
of pulmonary arterial pressure (PAP) [6]. Many studies support the use of chest 
CT in predicting PH [5-9] with some reporting correlation coefficients as high as 
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0.83 between main pulmonary artery diameter (MPAD) measurements and PAP 
[8]. With continued research in this field, it has become increasingly evident that 
this correlation may be substantially altered by the presence of specific 
comorbidities. For example, pulmonary fibrosis has recently been found to 
substantially alter the correlation between MPAD and PAP [11, 12]. 
In light of the recent identification of pulmonary fibrosis as a complicating 
factor and when considering the heterogeneity of clinical presentation in SSc, it is 
necessary that the relationship between MPAD and PAP be closely examined in 
the scleroderma population. Furthermore, all but one previous study [13] have 
evaluated the utility of the MPAD measurement in mixed populations comprised 
of very few SSc patients. This study will be the first to analyze the correlation 
between MPAD and PAP using a variety of chest CT protocols to access 
pulmonary involvement in a sample of scleroderma patients. In acknowledgment 
of the fact that a large number of cases of PAH occur in SSc patients with little to 
no fibrotic lung involvement and realizing that pulmonary fibrosis, when present, 
benefits most from early intervention, this study will focus on examining the 
correlation between MPAD and PAP in patients without the presence of fibrosis 
on chest CT as well as those with mild to moderate lung disease. 
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3.3 METHODS 
3.3.1 Patient Selection 
This study was a retrospective review of patient records and chest CT 
images contained electronically at our institution. Institutional review board 
approval as well as an informed patient consent waiver was obtained in order to 
conduct this research. To be eligible for the study, patients were required to 
have undergone both RHC and chest CT scan within a designated five year 
period between November 18, 2003 and November 18, 2008. Additionally, no 
more than six months was allowed between RHC and chest CT for patients to be 
included. In the event that a patient had multiple RHCs over the five year period 
indicated above, only the earliest RHC for which corresponding chest CT data 
was available was included in the study. A single rheumatology fellow performed 
electronic chart review to identify those patients meeting the American College of 
Rheumatology (ACR) criteria for the diagnosis of SSc [19]. Exclusions were 
made for patients whose chest CT showed signs of intubation or lung resection, 
whose mediastinal vascular delineation was judged as poor or worse (See CT 
Scoring Section), who had an insufficient number of image levels to determine 
overall inflammatory and fibrotic lung involvement, and who received nitric oxide 
prior to RHC. 
For purposes of analysis, patients were divided into two groups based on 
the absence (Group A) or presence (Group 8) of interstitial fibrosis on chest CT 
(see below). A subset of patients with available pulmonary function tests (PFTs) 
were also divided into groups based on forced vital capacity (FVC) 
measurements. To be included in this subgroup analysis, patients were required 
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to have PFTs within 3 months of chest CT. Patients with FVC > 70% predicted 
(Group C) were compared to those with FVC < 70 predicted (Group D) 
3.3.2 CT Scoring 
All CT images incorporated into this study were initially reviewed by one 
observer (J.R., with 15 years of radiologic experience) to determine the extent of 
ILD. The same observer also graded each image according to the quality of 
mediastinal vascular delineation. The extent of ILD was measured according to 
a previously reported protocol [38] with slight variations. Ground glass opacity 
(GGO) was evaluated using a six point scale (0 = absent, 1 = less than 5% of 
total lung, 2 = up to 250/0 of total lung, 3 = 25% to 49% of total lung, 4 = 50% to 
75% of total lung, 5 = greater than 75% of total lung) as was interstitial fibrosis (0 
= absent, 1 = interlobular septal thickening wlo honeycombing, 2 = 
honeycombing involving up to 25% of total lung, 3 = honeycombing involving 
from 250/0 to 490/0 of total lung, 4 = honeycombing involving from 500/0 to 750/0 of 
total lung, 5 = honeycombing involving greater than 750/0 of total lung). Vascular 
delineation was rated using a Likert scale (1 = very poor, 2 = poor, 3 = 
reasonable, 4 = good, 5 = very good)[7]. 
After eliminating all studies receiving a vascular delineation rating of less 
than "reasonable", two observers (M.K. and L.H.) independently reviewed the 
remaining images to measure the diameter of both the main pulmonary artery 
and the aorta. Measurements were made using computer calipers with both 
observers blinded to all clinical data regarding the research subjects. All images 
20 
were viewed at mediastinal window settings (window width = 390 HU, window 
level = 60 HU) with the mediastinum zoomed to full screen. The MPAD was 
defined as the greatest distance perpendicular to the long axis of the vessel as it 
passes anteroposteriorly across the base of the heart on supine full-chest 
sequence. The widest diameter of the aorta was also measured at the same 
scan level. 
3.3.3 Right Heart Catheterization 
In general, RHC was performed following the acquisition of right femoral 
vein access using a 7 French introducer sheath. A 7 French Swan-Ganz balloon 
tipped catheter was then introduced via the sheath and advanced through the 
right heart chambers into the pulmonary capillary wedge position. PAPs and 
pulmonary capillary wedge (PCW) pressures were recorded at rest for all 
patients. Pulmonary vascular resistance (PVR) was calculated using the 
following equation: PVR = (mPAP-mPCW)/CO where mPAP is the mean 
pulmonary artery pressure, mPCW is the mean pulmonary capillary wedge 
pressure, and CO is the cardiac output measured by either Fick's method or 
thermodilution. 
3.3.4 Statistical Analysis 
Categorical data are expressed as proportions while continuous variables 
are characterized by mean (S.D.) if normally distributed or median (range) if 
distributed otherwise. For continuous variables, comparisons between groups 
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were made using the Student's t-test or Mann-Whitney U test depending on the 
distribution of the data. Either the Chi-square test or Fisher's exact test was 
used to compare categorical data between groups. Correlations were examined 
using Pearson's coefficient for normal data and Spearman's coefficient if the 
assumption of normality could not be upheld. Given the limited sample size in 
this study, four of the following variables were chosen for incorporation into a 
multivariable linear regression model of mPAP based on the highest univariate 
correlations: age, gender, ethnicity, aortic diameter, body surface area, and 
presence or absence of fibrosis on chest CT. In order to investigate any potential 
interaction regarding the presence of interstitial fibrosis on chest CT and the 
relationship between mPAP and MPAD, a separate term was incorporated into 
the multivariable regression model. Receiver operating characteristic analysis 
was performed to determine the diagnostic accuracy of the MPAD measurement 
in predicting the presence of PH. 
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3.4 RESULTS 
3.4.1 Patient attributes 
After screening our patient base for the previously specified inclusion and 
exclusion criteria, 48 subjects remained for incorporation into this study. Table 1 
contains demographic information as well as clinical data for Group A and Group 
B. Data was available on a fraction of the patients with regard to several 
variables including PFT results. Of the 48 patients with suspected scleroderma, 
3 patients had undetermined connective tissue disease (UCTD), 1 patient had 
mixed sine scleroderma /sarcoidosis, 37 patients met the ACR criteria for the 
diagnosis of SSc, 2 patients met ACR criteria for SSc while also suffering from 
concomitant lupus, and 5 patients had insufficient records to accurately 
determine a diagnosis. No significant difference existed between Group A and 
Group B when considering CT-determined measurements of the mediastinal 
vasculature and invasive measures of pulmonary hemodynamics. The average 
MPAD in Group A was 31.3mm (S.D. 4.2mm) compared to 33.2mm (S.D. 
4.6mm) in Group B (p = 0.15). Upon evaluation of pulmonary hemodynamics, 
the average mPAP was found to be 27.5mmHg (C.1. 22.4-33.9mmHg) in Group A 
and 30.9mmHg (C.1. 26.9-35.5mmHg) in Group B (p = 0.35). Forced vital 
capacity data was available in 14 patients from Group A and 20 patients from 
Group B with mean values of 85.90/0 predicted (S.D. 19.8% predicted) and 64.2% 
predicted (S.D. 16.7% predicted) respectively (p = 0.002). Diffusion capacity for 
carbon monoxide (DLeo) was also available in 14 patients in Group At but only 
19 patients in Group B. Similar to FVC, a statistically significant difference in 
OLeo was found between the groups with Group A having a mean value of 50.10/0 
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predicted (C.I. 43.7-58.9% predicted) and Group B having a mean value of 
33.9% predicted (C.1. 28.8-40.7% predicted) (p = 0.001). 
Overall, 34 patients had available FVC data with Table 2 containing a 
comparison of important patient characteristics between Group C and Group O. 
The main differences between FVC-based groups pertain to patient age and 
MPAO. The average age of patients in Group C was 61.7 years (S.~. 11.7 
years) compared to 52.5 years (S.D. 11.3 years) in Group 0 (p = 0.03). On 
average, MPAO was larger (p = 0.032) in Group 0 (33.0mm, S.D. 3.8mm) versus 
Group C (30.1mm, S.D. 3.7mm). 
3.4.2 Univariate correlations 
Strong correlations between mPAP and MPAD were found in this study 
regardless of the presence or absence of mild to moderate interstitial fibrosis on 
chest CT (Table 3). The correlation coefficient between mPAP and MPAO in 
Group A (r = 0.68, p = 0.001) was very close to the value of the correlation 
coefficient found in Group B (r = 0.70, P < 0.0001) (See Figures below). 
Interestingly, when categorizing patients based on FVC, the correlation between 
mPAP and MPAD was substantially attenuated with Group C (r = 0.69, p = 
0.002) exhibiting a higher coefficient value than Group 0 (r = 0.42, P = 0.11) (See 
Figures below). Significant correlations were also present in both Group A (r = 
0.50, P = 0.03) and Group 8 (r = 0.47, P = 0.01) between mPAP and the ratio of 
MPAO to aortic diameter (AD), though these values were somewhat less in 
magnitude when compared to the correlation between mPAP and MPAD. In 
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contrast, marked variation between Group A (r = 0.51, P = 0.03) and Group B (r = 
0.09, P = 0.67) can be seen when PVR is correlated with MPAD/AD. This 
difference is lessened considerably when evaluating the relationship between 
PVR and MPAD. When the relationship between mPAP and MPAD/AD was 
evaluated in Group C and Group 0, a different pattern emerged than that seen 
when dividing patients based on CT measurements of interstitial fibrosis. While 
the correlation in Group C (r = 0.66, P = 0.003) remained similar to that seen 
between mPAP and MPAD, Group D (r = -0.09, p = 0.73) showed no significant 
correlation between mPAP and MPAD/AD. Group differences in the correlation 
between invasive measures of pulmonary hemodynamics and PFT results can 
also be appreciated from Table 3. 
3.4.3 Multivariable linear regression 
No relationship between mPAP and ethnicity, AD, or fibrosis group was 
identified on multivariable linear regression with MPAD serving as the primary 
measure of vascular dimension. Also, there was no interaction between MPAD 
and the presence or absence of fibrosis using this model (~hat = 0.07, P = 0.43). 
3.4.4 Diagnostic Accuracy 
Utility of the MPAD measurement was accessed by generating a receiver 
operating characteristic curve (See Figure below) and calculating the area under 
the curve (AUC = 0.86). An MPAD value of 30.8 mm yielded the highest 
sensitivity and specificity at 81.30/0 and 87.5% respectively. 
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3.5 DISCUSSION 
Frequently incorporated into the assessment of patients at risk for PH, 
MPAD has been valued by both radiologist and clinicians as an important 
indicator of elevated PAP with one study reporting a correlation coefficient as 
high as 0.83 [8] between these two measures. Recent literature [11, 12] has 
begun to challenge the previously identified relationship between mPAP and 
MPAD in select populations. Devaraj et al. [12] have demonstrated that no 
correlation exists between mPAP measured by RHC (mPAPRHC) and MPAD in a 
generalized population of patients suffering from diffuse pulmonary fibrosis. This 
finding was initially reported in a more specific group of idiopathic pulmonary 
fibrosis patients by Zisman et al. [11]. Perhaps most recently, the correlation 
between mPAPRHC and MPAD has been evaluated in a limited group of SSc 
patients with chest CT data gathered strictly under a pulmonary embolism 
protocol [13]. We sought to further analyze the correlation between mPAPRHC 
and MPAD in scleroderma patients using a diverse array of chest CT protocols. 
The single prior study [13] concerning the correlation (r = 0.35, P = 0.002) 
between mPAPRHC and MPAD in SSc patients initially evaluated this relationship 
in a group of 81 patients regardless of the extent of IlD. The authors then 
excluded patients with significant IlD, defined as either a disease extent> 20% 
according to a high-resolution CT scoring system set forth by Goh et al. [43] or 
FVC < 70% predicted on PFTs. The remaining subset of 63 patients exhibited a 
correlation between mPAPRHC and MPAD (r = 0.57, P < 0.001) that was 
noticeably superior to that seen in the original group of 81 patients. While these 
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results demonstrate that higher levels of ILD attenuate the correlation between 
mPAPRHC and MPAD, several questions remain unanswered. Which, if any, CT-
derived measures of ILD may account for this attenuation in correlation between 
mPAPRHC and MPAD? Furthermore, what is the stability of this correlation in 
patients with mild to moderate ILD on chest CT who may benefit most from 
interventions made early in the course of disease? 
One major difference between our study and that by Condliffe et al. [13] is 
the method by which patients were categorized prior to analysis of the correlation 
between mPAPRHC and MPAD. GGO is a more frequent finding in SSc than in 
patients with other types of lung disease such as idiopathic pulmonary fibrosis 
[44] and was highly prevalent in our sample. It is commonly thought that GGO 
represents alveolar and interstitial inflammation while a reticular pattern and/or 
honeycombing is more indicative of fibrosis [45-47]. Among the various 
radiologic signs of ILD, mainly the interstitial fibrosis score has been shown to 
correlate, if only weakly, with FVC [39]. With these issues in mind and when 
considering the fact that the interstitial fibrosis score allowed for a more uniform 
division of groups, we chose to primarily evaluate the role of this CT -derived 
measure of ILD with regard to the previously described attenuation in the 
correlation between mPAPRHC and MPAD. Our results show that the correlation 
between mPAPRHC and MPAD is maintained despite the presence of mild to 
moderate interstitial fibrosis on chest CT as represented by a fibrosis score of 3 
or less. Indeed, 75% of our patients with fibrosis (Group B) had a score of < 2, 
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representing the moderate nature of this type of interstitial involvement (data not 
shown). 
Despite the discovery that CT -derived fibrosis score did not influence the 
correlation between mPAPRHC and MPAD in our sample, an interesting finding 
resulted when categorizing patients based on available PFT data. Values of FVC 
< 70% predicted were associated with a considerably lower correlation (r = 0.42, 
P = 0.11) between mPAPRHC and MPAD than values of FVC > 700/0 predicted 
(r = 0.69, P = 0.002). One possible explanation for this difference in correlation 
could be that the criterion of FVC < 70% predicted selects out patients with a 
greater extent of disease on chest CT scan [43]. In fact, 37.5% of our population 
with an FVC < 70% predicted also had a fibrosis score of 3. Thus, all but one 
patient in our study with a fibrosis score of 3 was incorporated into Group D. 
Notwithstanding this discrepancy in fibrosis score distribution when grouping 
patients based on FVC, it is unlikely that the increase in CT-measured fibrosis is 
responsible for the attenuation in correlation between mPAPRHC and MPAD seen 
in Group D. This is evidenced by the finding that the correlation coefficient 
between mPAPRHC and MPAD in patients with a fibrosis score of 3 (r = 0.71, 
P = 0.07) is relatively strong and trends toward statistical significance in spite of 
an extremely low sample size (See Figure below). Therefore, to reiterate the 
finding from above, the appearance of fibrosis involving up to 50% of the lungs 
on CT does not influence the correlation between mPAPRHC and MPAD in 
scleroderma patients. The revelation that FVC attenuates this correlation may 
reflect the relatively weak association between CT-measured pulmonary fibrosis 
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and clinically available measurements of lung function in this population [39]. 
Contrary to multiple prior studies [7, 12, 13], we did not find MPAD/AD to 
strengthen the correlation with mPAPRHC in any group. MPAD/AD was most 
noticeably inferior to MPAD as a correlate of mPAPRHC in Group D. Group D also 
exhibited significantly larger MPAD values than Group C with no difference in AD 
or mPAP between the groups. When combined, these factors point to 
mediastinal traction [7, 11, 42] as a possible explanation for the poor 
performance of MPAD/AD in Group D, however, concomitant systemic arterial 
disease may also contribute as such patients were not excluded from this study. 
This study has several limitations including a patient sample that was 
gathered solely from a tertiary care center. Another major limitation was the lack 
of available PFT data for 14 of the 48 patients in this study. Therefore, subjects 
with PFT data may represent a subset of patients with more severe disease. In 
addition, patients were grouped for analysis based primarily on CT-derived 
measurements of fibrosis alone. As discussed earlier, this grouping was 
necessary in order to isolate the contribution of fibrosis to the attenuation in 
correlation between MPAD and mPAPRHC. The interval between RHC and chest 
CT was another potential limitation to this study, although, up to 9 months 
between tests has been reported in the literature [12]. 
In summary, this study suggests that the presence of fibrotic lung disease 
on chest CT scan does not influence the correlation between mPAPRHC and 
MPAD in scleroderma patients with mild to moderate degrees of total pulmonary 
involvement. On the other hand, categorizing patients according to FVC may 
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identify those in whom MPAD is a poor predictor of mPAPRHC. Currently 
available clinical algorithms, such as that proposed by Goh et al. [43] and further 
exploited by Condliffe et al.[13], may be useful for predicting overall morbidity 
and mortality in SSc, but limited in utility when assessing morbidity related to PH 
in this complex and protean disease. Algorithms of this nature may be 
excessively stringent if used to evaluate suspected PH, thereby resulting in the 
avoidance of MPAD measurements from patients with higher levels of pulmonary 
fibrosis on chest CT. Finally, with a positive predictive value approaching 930/0 
in this study, the measurement of MPAD on chest CT may hold future promise in 
avoiding unnecessary RHC and contribute to PH screening when incorporated in 
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PAH, % of mPAP 
~ 25 with pew ~ 
15 
N(Group A:B) Total 
20:28 81.3 
13:19 68.8 
Group A Group B P-value 
80.0 82.1 1.00* 
84.6 57.9 0.14* 
Data analyzed using the following: ¥Student's t-test, *Fisher's Exact test, Chi-Square, €Wilcoxin Rank-Sum 
nVariable was log-transformed. Data represented as antilog of mean (confidence interval). 
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mPAPRHc was log-transformed for all univariate correlations. 
*Spearman's correlation coefficient. 
rvariable was log-transformed in addition to mPAPRH:-
GroupC 
0.69 0.001 0.42 0.11 
Figure 1: Demonstration of MPAD Measurement on Axial CT Image 
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Figure 3: Log mPAP vs. MPAD in Group B 
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Figure 4: Log mPAP VS. MPAD in Group C 
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Figure 5: Log mPAP vs. MPAD in Group 0 
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Figure 6: Log mPAP VS. MPAD in Patients with Fibrosis Score of 3 
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Figure 7: ROC Curve for MPAD Measurement 
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